Dissociated amyloid-beta antibody levels as a serum biomarker for the progression of Alzheimer's disease: a population-based study.
about
Autoantibodies in Alzheimer's disease: potential biomarkers, pathogenic roles, and therapeutic implicationsBiomarkers in Alzheimer's disease: past, present and future.The future of blood-based biomarkers for Alzheimer's disease.Mitochondrial dynamics in Alzheimer's disease: opportunities for future treatment strategies.Antigen-bound and free β-amyloid autoantibodies in serum of healthy adults.Identifying and validating biomarkers for Alzheimer's disease.ELISA measurement of specific non-antigen-bound antibodies to Aβ1-42 monomer and soluble oligomers in sera from Alzheimer's disease, mild cognitively impaired, and noncognitively impaired subjectsIncreased levels of antigen-bound β-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer's disease patients.Increased Number of Plasma B Cells Producing Autoantibodies Against Aβ42 Protofibrils in Alzheimer's Disease.Plasma amyloid-β levels and prognosis in incident dementia cases of the 3-City StudyDNA methylation as a biomarker for neuropsychiatric diseases.Pathogenic and physiological autoantibodies in the central nervous system.Time-course global proteome analyses reveal an inverse correlation between Aβ burden and immunoglobulin M levels in the APPNL-F mouse model of Alzheimer disease.Neurodegenerative processes in Alzheimer’s disease: an overview of pathogenesis with strategic biomarker potential
P2860
Q26740418-E439AA2F-1419-4A33-8C27-BCB72E7A610BQ33791646-D4B34816-97BC-40DD-9B45-2E1749C26C72Q34026317-F10DEC21-7A6D-47A7-921A-D5A961F33B0DQ34073939-C13B7B63-F84A-42A2-9230-07405E47C4FBQ34413715-A29BE49C-0121-4AE5-A457-08B7FC23ED58Q34468961-CA155DE2-185F-4019-9406-1DF06F1EFC8EQ35184148-48CBCF28-2936-4873-A815-027D6B16217BQ37024947-43A3A137-C171-48BF-8905-982FA7DBA374Q37044228-27351F34-30D3-46B1-8306-3D24AE57A64CQ37693190-5E2B3BA3-DB8E-43D9-BA53-87DF866EF58DQ37960643-FAE8E75C-A122-44BA-83DC-67421EDE6F56Q38020957-E351DF3C-6086-4810-9FF4-E1C0703E6F55Q41498857-C5991053-48C6-47E9-9F20-50E91828B98AQ57341313-23F60CC1-5D4C-44A6-9552-93AE569132BD
P2860
Dissociated amyloid-beta antibody levels as a serum biomarker for the progression of Alzheimer's disease: a population-based study.
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Dissociated amyloid-beta antib ...... ase: a population-based study.
@ast
Dissociated amyloid-beta antib ...... ase: a population-based study.
@en
type
label
Dissociated amyloid-beta antib ...... ase: a population-based study.
@ast
Dissociated amyloid-beta antib ...... ase: a population-based study.
@en
prefLabel
Dissociated amyloid-beta antib ...... ase: a population-based study.
@ast
Dissociated amyloid-beta antib ...... ase: a population-based study.
@en
P2093
P2860
P1476
Dissociated amyloid-beta antib ...... ase: a population-based study.
@en
P2093
Alan Lerner
David J Bonda
Katarzyna A Gustaw-Rothenberg
Massimo Tabaton
Sandra L Siedlak
P2860
P356
10.1016/J.EXGER.2009.10.003
P577
2009-10-09T00:00:00Z